First published January 4, 2016 - More info
Tiffany Chang, Kimberly Krisman, Emily Harding Theobald, Jin Xu, Jon Akutagawa, Jennifer O. Lauchle, Scott Kogan, Benjamin S. Braun, Kevin Shannon
Original citation: J Clin Invest. 2013;123(1):335–339. doi:10.1172/JCI63193.
Citation for this corrigendum: J Clin Invest. 2016;126(1):404. doi:10.1172/JCI85325.
The genotype of the Nf1 mutant mice was incorrectly described. The correct text for Methods appears below.
Mice and treatment procedures. Mx1-Cre;Nf1tm1Par/tm1Tyj (referred to as Mx1-Cre;Nf1flox/–) and control mice (Nf1flox/+) were generated and treated with pIpC (Sigma-Aldrich) at 3–5 days, as described previously (16).
In addition, corrected sentences describing the Nf1 mutant mice in the Introduction and Results and Discussion appear below.
To address this question, we administered 901 to Mx1-Cre;Nf1flox/– mice with MPN.
We first assessed the pharmacodynamic properties of 901 in WT and Mx1-Cre;Nf1flox/– (Nf1 mutant) mice that received an oral gavage dose of 5 mg/kg/d for 5 days.
We randomly assigned Mx1-Cre;Nf1flox/– mice (n = 35) and their WT littermates (n = 38) to treatment with 901 (at a daily dose of 5 mg/kg) or control vehicle for 10 weeks or until the mice became moribund.
Progressive anemia with elevated reticulocyte counts and massive splenomegaly suggested that Mx1-Cre;Nf1flox/– mice with MPN have ineffective erythropoiesis.
In striking contrast, profiling revealed a largely inverted ratio of early-to-late erythroblasts in Mx1-Cre;Nf1flox/– mice, with 10-fold expansion in the percentage of cells in region II, and a reciprocal decline in the number of erythroblasts progressing to region IV (Figure 2C).
To further characterize the hematopoietic compartment in Mx1-Cre;Nf1flox/– with MPN, we enumerated KLS (c-Kit+lin–Sca-1+) cells and myelo-erythroid progenitor populations by flow cytometry (11, 12).
In addition, corrected sentences describing the Nf1 mutant mice in the figure legends appear below.
[Figure 1] 901 reduces myeloproliferation and enhances erythropoiesis in Mx1-Cre;Nf1flox/– (Nf1) mice.
[Figure 2] Hematopoietic tissues from 6-month-old Mx1-Cre;Nf1flox/– (Nf1) and WT mice treated with 901 or vehicle were analyzed at the end of the trial.
[Figure 3] 901 normalizes early myelo-erythroid populations in Mx1-Cre;Nf1flox/– (Nf1) mice.
Finally, the online version of the supplemental data has been updated to indicate the correct genotype of Nf1 mutant mice in Supplemental Figures 2–5.
The authors regret the errors.